LIF and glomerular disorder: The inhibitors which are tested in clinical trials for glomerular diseases target the activation pathways i.e., the lectin pathway via MASP-2, the central component C3 (APL1 and Amy101), the alternative pathway convertase via Factor D (ACH4471), Factor B (LPN 023), target the terminal pathway via C5 (Eculizumab, LFG-316), by blocking C5 synthesis in the liver via C5-siRNA (Alnylam), or directly interfering with the inflammatory C5a—C5aR1 axis (IFX1; InflaRX, and Avacopan; Chemocentryx).